Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
16 studies found for:    alpharadin | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
Condition: Prostate Cancer
Intervention: Drug: Alpharadin
2 Recruiting Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Pain
Intervention: Drug: Radium-223
3 Recruiting Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Condition: Prostatic Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Matching placebo (normal saline);   Drug: Abiraterone;   Drug: Prednisone/Prednisolone
4 Recruiting Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
5 Not yet recruiting Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Other: Background hormonal therapy
6 Not yet recruiting Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Drug: Exemestane;   Drug: Everolimus
7 Recruiting Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
8 Recruiting A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Condition: Prostatic Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo,BAY88-8223);   Drug: Abiraterone acetate;   Drug: Prednisone;   Drug: Enzalutamide
9 Recruiting Radium-223 Dichloride (Ra-223 Cl2) Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
10 Recruiting Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
11 Not yet recruiting BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Condition: Non Small Cell Lung Cancer With Bone Metastatses
Intervention: Biological: Xofigo
12 Recruiting Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
Condition: Bone Metastatic Castration-Resistant Prostate Cancer
Interventions: Other: Biomarker analysis;   Drug: Administration of radium-223
13 Recruiting Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
14 Recruiting Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Condition: Sarcoma
Intervention: Drug: Ra-223 Dichloride
15 Not yet recruiting Phase III Radium 223 mCRPC-PEACE III
Condition: Prostate Cancer
Interventions: Drug: Ra223;   Drug: Enzalutamide
16 Recruiting Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Condition: Prostate Cancer
Intervention: Drug: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone

Indicates status has not been verified in more than two years